Viagra vs. Tadalafil (Generic): Switching Between Them

How Sildenafil and Tadalafil Actually Work

Both drugs block phosphodiesterase type 5, the enzyme that degrades cyclic GMP in penile smooth muscle. The result is the same: prolonged smooth-muscle relaxation and increased blood flow during sexual stimulation. Neither drug creates an erection without arousal. The mechanism was first validated in the landmark Goldstein et al. trial (N=532), which demonstrated that sildenafil 25 to 100 mg improved erections in 69% of all attempts versus 22% with placebo 1.

Where they diverge is selectivity. Sildenafil has modest cross-reactivity with PDE6, the isoenzyme in retinal photoreceptors, which explains the blue-tinted vision some men report at higher doses 2. Tadalafil has minimal PDE6 affinity but greater PDE11 binding. PDE11 is expressed in skeletal muscle and the prostate, a pharmacologic detail that may contribute to the myalgia and back pain occasionally seen with tadalafil 3.

Both remain first-line therapy for erectile dysfunction per the American Urological Association (AUA) 2018 guideline, which states: "PDE5 inhibitors should be offered as first-line therapy for ED unless contraindicated" 4.

Pharmacokinetics: The 36-Hour Difference

Sildenafil reaches peak plasma concentration (Tmax) in roughly 60 minutes on an empty stomach, with a terminal half-life of 3 to 5 hours. A high-fat meal can delay that peak by another 60 minutes and reduce Cmax by about 29% 5. That food sensitivity is the single most common reason men report inconsistent results with sildenafil.

Tadalafil reaches Tmax in about 2 hours. Its half-life is 17.5 hours. Because therapeutic drug levels persist far longer, Brock et al. (N=1,112) showed that tadalafil 20 mg improved intercourse success rates at 24 hours (59.2%) and even at 36 hours (a finding no other PDE5 inhibitor has matched) 3. That prolonged window earned it the colloquial name "the weekend pill."

The practical difference: sildenafil demands timing. A man must plan dosing within 1 to 2 hours of anticipated intercourse and avoid eating a heavy meal beforehand. Tadalafil decouples the pill from the moment. This distinction matters most for men in stable relationships who prefer spontaneity over scheduling.

A 2006 preference study published in European Urology found that among men who tried both drugs, 73% preferred tadalafil, primarily citing the longer window and reduced need to time meals 6.

Daily Dosing: An Option Unique to Tadalafil

Tadalafil is the only PDE5 inhibitor with FDA approval for continuous daily use at 2.5 or 5 mg 7. Daily dosing maintains a steady-state plasma level, which means erectile support is always present without planning a dose before sex.

In a 2007 randomized trial (N=268), tadalafil 5 mg daily produced a mean IIEF-EF domain improvement of 6.1 points versus 1.2 points for placebo after 12 weeks (P<0.001) 8. The daily approach also benefits men with concurrent lower urinary tract symptoms from benign prostatic hyperplasia (BPH). Tadalafil 5 mg daily reduced International Prostate Symptom Score (IPSS) by 4.9 points from baseline, comparable to tamsulosin 9.

Sildenafil has no approved daily-dosing regimen. Some clinicians prescribe it off-label at 25 mg daily for post-prostatectomy penile rehabilitation, but that use remains investigational and is not supported by the same body of evidence.

For men with both ED and BPH symptoms, tadalafil 5 mg daily can replace two separate prescriptions. That simplification reduces pill burden and may improve adherence.

Efficacy: Is One Actually Better?

No large, well-powered, head-to-head superiority trial has been published comparing sildenafil and tadalafil using the same primary endpoint in the same population. The available crossover and preference studies consistently show comparable efficacy on validated instruments like the IIEF.

A 2011 Cochrane-style meta-analysis of 82 randomized trials (N=47,626) found that all PDE5 inhibitors produced statistically similar improvements in IIEF scores when used at recommended doses, with no class member demonstrating consistent superiority 10. The authors noted: "Differences between agents are best characterized by their pharmacokinetic profiles rather than by differences in efficacy."

What does differ is the type of efficacy that matters to each patient. Sildenafil may produce a subjectively firmer erection in some men because its faster Tmax delivers a sharper peak plasma concentration. Tadalafil wins on flexibility. Neither advantage translates to a universal recommendation.

The AUA guideline reinforces this neutrality: "Selection of a PDE5 inhibitor should be based on patient preference, cost, and formulary availability rather than presumed differences in efficacy" 4.

Side Effects Compared

Both drugs share class-wide adverse effects: headache, flushing, nasal congestion, and dyspepsia. Their side-effect profiles diverge in two specific areas.

Sildenafil's PDE6 cross-reactivity produces dose-dependent visual disturbances (blue tinge, increased light sensitivity) in roughly 3% to 11% of users at 100 mg 5. These visual changes are transient, typically lasting less than a few hours, and resolve without intervention.

Tadalafil causes back pain and myalgia in 4% to 6% of men taking 10 or 20 mg on demand, likely mediated by PDE11 inhibition in skeletal muscle 7. The back pain usually appears 12 to 24 hours after dosing and resolves within 48 hours. It tends to diminish with repeated use.

Headache rates are similar across both drugs at recommended doses (roughly 15% to 16%). Flushing is slightly more common with sildenafil. Neither drug has demonstrated increased cardiovascular risk in men without contraindicated nitrate use, a finding confirmed in a 2021 meta-analysis of 109 trials 11.

Men on organic nitrates (nitroglycerin, isosorbide mononitrate or dinitrate) cannot use either drug. This is an absolute contraindication shared by the entire PDE5 class.

How to Switch from Sildenafil to Tadalafil (or Back)

Switching requires no washout period. The pharmacokinetics of these drugs do not produce dangerous accumulation if doses overlap slightly, because both act on the same target. The practical protocol is simple.

Switching from sildenafil to tadalafil on demand (10 or 20 mg): Take the first tadalafil dose at the next planned sexual encounter, at least 24 hours after the last sildenafil dose. The 24-hour gap is conservative, not mandatory. Sildenafil clears within 6 to 8 hours.

Switching from sildenafil to tadalafil daily (2.5 or 5 mg): Start the daily tadalafil the day after the last sildenafil dose. Steady state takes about 5 days. Some men notice weaker initial response during days 2 through 4; this is expected and resolves.

Switching from tadalafil to sildenafil: Because tadalafil's half-life is 17.5 hours, residual drug levels persist for 48 to 72 hours. Take sildenafil no sooner than 48 hours after the last tadalafil dose to avoid additive vasodilation. This is the one scenario where a brief gap is clinically prudent.

Dr. Arthur Burnett, professor of urology at Johns Hopkins and lead author on the AUA erectile dysfunction guideline, has noted: "Switching PDE5 inhibitors is among the most common interventions in sexual medicine practice. A man who does not respond optimally to one agent should trial at least one alternative before concluding that PDE5 inhibitors have failed" 4.

Cost and Insurance Considerations

Brand-name Viagra now competes with multiple generic sildenafil manufacturers. As of 2025, generic sildenafil 100 mg (often split into two 50 mg doses) costs $0.30 to $2.00 per tablet at most pharmacies through discount programs like GoodRx. Generic tadalafil 20 mg ranges from $0.40 to $3.00 per tablet 12.

Tadalafil daily (5 mg, 30-tablet supply) typically runs $15 to $45 per month at generic pricing. Compared with on-demand dosing at 4 or more uses per month, daily tadalafil may actually cost less per encounter while also delivering the BPH benefit.

Insurance coverage for ED medications varies. Medicare Part D plans are specifically prohibited from covering PDE5 inhibitors for erectile dysfunction under the Social Security Act, though they may cover tadalafil 5 mg when prescribed for BPH 7. Commercial plans increasingly cover generics, often with a quantity limit of 6 to 12 tablets per month.

For men paying cash, the cost difference between sildenafil and tadalafil is now marginal. Decision-making should rest on pharmacokinetic fit, side-effect profile, and whether daily dosing is desirable.

Who Should Consider Switching

Several clinical scenarios favor one drug over the other.

Consider tadalafil if: You dislike timing your dose to a narrow activity window. You find that high-fat meals interfere with sildenafil's reliability. You have concurrent BPH or lower urinary tract symptoms. You prefer spontaneity over scheduling.

Consider sildenafil if: You prefer on-demand dosing and do not want continuous medication. You experience back pain or myalgia with tadalafil. You respond well to a rapid-onset, shorter-acting agent. Cost optimization through pill-splitting (100 mg tablets split into 50 mg halves) is a priority.

Stay with your current drug if: It works reliably, produces tolerable side effects, and fits your lifestyle. There is no clinical reason to switch a drug that is performing well. The AUA guideline explicitly recommends trialing a PDE5 inhibitor on at least 6 to 8 occasions before labeling it a treatment failure 4.

Contraindications Shared by Both Drugs

Both sildenafil and tadalafil carry the same absolute contraindication: concurrent use of organic nitrates (nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, amyl nitrite). Combining a PDE5 inhibitor with any nitrate can cause severe, potentially fatal hypotension 5.

Alpha-blockers require caution. Sildenafil labeling recommends a minimum 4-hour separation from alpha-blocker dosing. Tadalafil labeling advises starting at 5 mg when co-prescribed with an alpha-blocker except tamsulosin 0.4 mg, which has demonstrated hemodynamic safety with tadalafil 7.

Men with recent myocardial infarction (within 90 days), unstable angina, or uncontrolled hypertension (BP >170/100 mmHg) should avoid both agents until cleared by cardiology. The Princeton III Consensus Conference (2012) provides a risk-stratification framework for sexual activity in cardiac patients 13.

Men taking strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) need dose reductions with both drugs, though the magnitude differs. Tadalafil maximum dose falls to 10 mg per 72 hours with potent CYP3A4 inhibition; sildenafil should not exceed 25 mg per 48 hours.

Combination with Other ED Treatments

Neither PDE5 inhibitor should be combined with another PDE5 inhibitor. Taking sildenafil and tadalafil together (or overlapping doses during a switch) provides no added benefit and increases the risk of hypotension, headache, and priapism.

PDE5 inhibitors can, however, be safely combined with certain other modalities. Vacuum erection devices, penile injection therapy (alprostadil or trimix), and psychosexual counseling can all complement PDE5 inhibitor use. A 2019 review in The Journal of Sexual Medicine found that combination therapy (PDE5 inhibitor plus intracavernosal injection at reduced dose) improved satisfaction in men with partial PDE5 inhibitor response 14.

Testosterone replacement therapy may enhance PDE5 inhibitor response in men with documented hypogonadism (total testosterone <300 ng/dL). A randomized trial (N=140) showed that adding testosterone gel to sildenafil increased IIEF scores by 3.6 additional points compared with sildenafil alone in hypogonadal men 15.